1496-VIDA: Protease-Initiated Antiviral mRNA Therapy

This research article introduces VIDA, an innovative antiviral mRNA therapy designed to combat diverse viral threats by leveraging the host's own cell death mechanisms. Researchers engineered gasdermin proteins to include specific cleavage motifs that only activate in the presence of a viral protease. When a cell is infected, the VIDA mRNA triggers lytic cell death, effectively destroying the virus's replication site while simultaneously alerting the immune system through the release of inflammatory signals. The study demonstrates success against hepatitis A, Zika, and SARS-CoV-2, proving the platform's versatility across different virus families. Furthermore, the team utilized generative AI to optimize these molecular designs for enhanced safety and potency. Ultimately, this "kill-and-alert" strategy represents a programmable and universal approach to modern antiviral therapeutics.References:Li L, Yan X L, Wang H Y, et al. Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy[J]. Cell, 2026.前往小宇宙评论区与主播互动